Nick Veomett

Company: Artiva Biotherapeutics, Inc

Job title: Vice President Corporate Development

Bio:

Nicholas Veomett is Vice President of Corporate Development at Artiva Biotherapeutics, a clinical-stage company developing off-the-shelf natural killer (NK) cell therapies for autoimmune disease and cancer. Since joining Artiva in 2021, he has led strategic initiatives, including the advancement of AlloNK®, which has demonstrated clinical activity and tolerability in B-cell NHL, and is currently in clinical trials for autoimmune indications including RA, Sjögren’s disease, myositis, systemic sclerosis, and SLE/LN. Previously, Dr. Veomett held corporate development roles at Vividion Therapeutics and was an Engagement Manager at McKinsey & Company. He earned his Ph.D. in Pharmacology from Weill Cornell Medical College, with research at the Sloan Kettering Institute. 

Seminars:

Unlocking New Immune Pathways: Discussing B-Cell Depletion & Beyond in Autoimmune Therapy 9:10 am

Discussing the latest B-cell depletion data across diseases to assess effectiveness and potential for expansion into dermatological diseases such as psoriasis Evaluating if B-cell depletion remains the most promising approach and exploring the potential to move beyond B-cell targeting (including, Mast Cells, T-cells, Macrophages, Myeloid Cells and more) Exploring immune cell depletion across disease indications…Read more

day: Day Two